Dr. Vikram Sengupta, MD

Dr. Sengupta practices at Mission Medical Care in Rockville Centre, New York.

Dr. Sengupta's NPI, 1740568153, was assigned on August 2, 2011. Dr. Sengupta graduated from Yale University School of Medicine in 2011. Dr. Sengupta holds Massachusetts license 266344.

Dr. Sengupta's primary practice is Mission Medical Care, at 265 Sunrise Hwy, Rockville Centre, NY 11570 in Nassau County. The practice phone is (212) 803-3339.

Dr. Sengupta's primary practice is Mission Medical Care in Rockville Centre, New York. Dr. Sengupta is also affiliated with Wynn Hospital. The medical group on file is Mission Medical Care. Dmand AI also links Dr. Sengupta to 1 more hospital, 2 group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Sengupta practices, 4 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Sengupta's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dmand AI has Dr. Sengupta's licenses on file in 2 states: Massachusetts and New York.

CMS data shows 979 Medicare services from Dr. Sengupta across 11 procedure codes in 2024, for 123 Medicare patients. Medicare paid $28,285 for them. Every service was in an office.

CMS counts 123 Medicare patients who saw Dr. Sengupta in 2024. The largest group is 75 to 84, with 41 patients. 75% of them have arthritis, and 75% have high blood pressure. 20% are also on Medicaid. Their average risk score is 1.23, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Sengupta's median patient age at 59, with 61% women.

In 2024, Dr. Sengupta wrote 189 Medicare Part D claims for 75 patients. 97% of them were for generic drugs. CMS names the drug for 109 of them, across 5 drugs with 11 or more claims each, at $2,241 in total drug cost. In 2018, CMS named 185 claims across 7 drugs.

Dr. Sengupta accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Sengupta as offering telehealth.

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 4 papers to Dr. Sengupta, published from 2020 to 2024. 2020 was the busiest year, with 2. The most frequent topics are COVID-19, Mesenchymal Stem Cells and Betacoronavirus. Dr. Sengupta has published most often in Stem Cells Dev. Dr. Sengupta's most frequent co-authors are Angel Amado Lazo, MD, Amy Lee Lightner, MD and Nicholas John Bremer, MD.

Dmand AI links Dr. Sengupta to 6 clinical trials, 2 of them phase 1 studies. 1 is still active or recruiting. Conditions studied include Respiratory Distress Syndrome, Respiration Disorders and Colitis, Ulcerative. Direct Biologics, LLC sponsors the most, 6.

CMS Open Payments shows 146 general payments to Dr. Sengupta from 40 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 82% of the total. Boston Scientific Corporation paid the most, $1,423.

Dr. Sengupta graduated from Yale University School of Medicine in 2011.